News

Parsons Corp Sees Growth with Increased Price Target from Jefferies

Parsons Corp Sees Growth with Increased Price Target from Jefferies

Parsons Corp's Positive Outlook Following Jefferies Upgrade

Jefferies has recently reinforced its supportive stance on Parsons Corp. (NYSE: PSN), affirming a Buy rating and raising the price target from $125 to $130. This adjustment reflects the company’s remarkable performance thus far and optimistic growth prospects for the future.

Impressive Organic Growth and Strong Financials

Parsons Corp has reported a striking organic growth rate of 26% year-to-date. This impressive figure has prompted the company to update its revenue guidance, now estimating an over 22% growth for the full year. Such performance is a clear indicator of Parsons' resilient operational strategy and market positioning.

Robust Backlog and Pipeline

Further emphasizing the company's strength is its substantial $9 billion backlog, complemented by a $13 billion unbooked pipeline. With a win rate exceeding 70%, Parsons is on track to maintain double-digit revenue growth that surpasses analyst estimates of 8% and 7% for the years 2025 and 2026, respectively.

Monitoring Critical Infrastructure Margins

While the outlook is predominantly positive, Jefferies points to the Critical Infrastructure (CI) margins currently sitting at 7.1% as an area that requires attention. The legacy joint ventures are constraining margins, and if these are excluded, the margins would rise to around 10%. Analysts anticipate an improvement in margins as these legacy programs conclude by 2025 and 2026.

Future Expectations and M&A Impact

The investment firm’s analysis also encapsulates the potential implications of mergers and acquisitions on Parsons Corp's growth trajectory. With a forecasted annual margin expansion of 25 basis points and expectations for pipeline conversion, there is an anticipated 15% upside for Parsons' shares concerning the new price target.

Record Third-Quarter Results

Parsons Corporation recently achieved its record third-quarter results, with revenues surging to $1.8 billion, signifying a 28% increase compared to the previous year. This growth has been catalyzed by a 31% rise in adjusted EBITDA, prompting the corporation to elevate its full-year guidance for both revenue and adjusted EBITDA.

Segment Highlights and Strategic Adjustments

Notably, the Federal Solutions segment has exhibited a remarkable 42% increase in revenue, while the Critical Infrastructure segment has seen a growth of 10%. Despite the challenges of a $23.5 million write-down, Parsons is strategically transitioning from legacy contracts, refocusing on its core design and program management roles to streamline operations.

Fiscal 2024 Projections

Looking ahead, Parsons Corporation remains optimistic with its revised fiscal 2024 guidance, projecting revenues between $6.6 billion and $6.8 billion, alongside adjusted EBITDA estimates of $590 million to $620 million. The anticipated revenue growth rate for 2025 is just under 13%, with contributions from acquisitions expected to exceed $200 million.

InvestingPro Insights on Parsons Corp

Supporting the promising outlook for Parsons Corp is real-time data from InvestingPro, which indicates a market capitalization of $11.68 billion. There has been a significant revenue increase of 28.35% over the past twelve months, reinforcing Jefferies' claims about the company's organic growth.

Analysts' Confidence Growing

Further bolstering this positive sentiment, nine analysts have revised their earnings estimates upwards for the upcoming period, indicating rising confidence in Parsons' financial performance. With a total return of 94.52% over the past year and an impressive 75.41% year-to-date return, the company's stock performance aligns with Jefferies' predictions of an upside for shares.

Final Insights and Acquisition Contributions

Parsons Corp's ability to maintain a strong performance trajectory makes it a compelling prospect for investors. The strategic acquisition of companies like BlackSignal Technology and BCC Engineering has been pivotal in enhancing its operational capabilities and supporting growth.

Frequently Asked Questions

What did Jefferies do with Parsons Corp's price target?

Jefferies raised the price target for Parsons Corp from $125 to $130, maintaining a Buy rating due to strong growth prospects.

What is the current growth rate reported by Parsons Corp?

Parsons Corp reported an organic growth rate of 26% year-to-date, with expectations of over 22% growth for the full year.

How has Parsons Corp's revenue changed recently?

The company achieved record third-quarter revenues of $1.8 billion, representing a 28% increase year-over-year.

What segments contributed to Parsons' growth?

The Federal Solutions segment saw a 42% revenue increase, while the Critical Infrastructure segment grew by 10%.

What are the projections for Parsons Corp in fiscal 2024?

Parsons now expects revenues between $6.6 billion and $6.8 billion, with adjusted EBITDA ranging from $590 million to $620 million.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Bybit Expands On-Chain Access: Japanese Equity Focus

Updated Category News Views 5

Bybit's Bold Foray Into Japanese Equities Isn't every trader just itching to talk about Japan these days? Well, Bybit's got your back with its latest maneuvers. The platform is broadening its scope by diving headfirst into Japanese equities with a fresh offering—JPE backed by JX, no less. Bybit's RWA Earn platform isn't sticking to the boring fixed-income strategy...

Continue Reading
BMZ's RB-900 E-Bike Battery Shakes Up U.S. Market

Updated Category News Views 22

A New Ride: BMZ's Strategic Move Look, the e-bike world isn't just pedaling; it's racing ahead, and BMZ Battery Solutions Group is shifting gears. From November 11–12, 2026, the company's going to stir the pot at Micromobility America, introducing its POWER2RIDE RB-900 e-bike battery—a powerhouse eager to make its mark in the U.S. e-bike scene. We're talking real...

Continue Reading
Telespazio & Rivada Forge Secure Satellite Network

Updated Category News Views 96

Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...

Continue Reading
Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

Updated Category News Views 166

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

Continue Reading
PNU and Cellenkos Team Up for Biotech Advancements

Updated Category News Views 25

Paving New Paths in Biotech Collaboration When a university and a biotech company shake hands to bolster their capabilities in the ever-evolving field of clinical trials and cell and gene therapies, investors and industry buffs alike should perk up. The College of Medicine at Princess Nourah bint Abdulrahman University (PNU) has just inked a Memorandum of Understanding...

Continue Reading
Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 193

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
Tigo Energy Faces Class Action: Investor Deadline Looms

Updated Category News Views 61

Unpacking Tigo's Rollercoaster: Lawsuit & Market Reaction They sometimes say, "When it rains, it pours." For Tigo Energy, it’s been more a downpour than a drizzle. Here we are, chasing down what's going on with Tigo Energy (NASDAQ:TYGO), fresh off the heels of a class action fuss that's grabbed every investor's attention. If you've got a stake, or even a passing...

Continue Reading
Tuya Gears Up for Q3 Financial Results Amid AI Growth

Updated Category News Views 34

Tuya's Third Quarter: What Are We Watching? Alright, folks, Tuya's about to drop their third quarter financial results like it's a hot potato. Circle November 23, 2026, on your calendars. That's when we'll get the goods on whether this AI cloud heavyweight is coasting or crushing it. Conference Call: The Gathering of Numbers The number-crunching brigade kickstarts at 7:30...

Continue Reading
O-I Glass Faces Class Action: Investor Implications

Updated Category News Views 130

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

Updated Category News Views 154

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Continue Reading

Top 5 Most Recently Viewed Articles

Total Shares and Voting Rights Update for FNAC Stockholders

Updated Category News Views 131

An Overview of Total Shares and Voting Rights Understanding the total number of shares and associated voting rights is essential for both current and potential investors in any publicly traded company, including FNAC. This information reflects the company’s financial health and governance structure, keeping investors informed about their stake in the organization. Key...

Continue Reading
Scatec ASA Expands Renewable Energy with Bond Buy-Back Move

Updated Category News Views 221

Scatec ASA Takes Bold Steps in Sustainable Finance Recently, Scatec ASA has made headlines by engaging in the buy-back of its outstanding bonds. This move closely follows their announcement regarding the issuance of new green bonds, demonstrating a proactive approach to financial management and sustainability in the renewable energy sector. Bonds Buy-Back Highlights In a...

Continue Reading
Discover How Real-World Data Fuels the Patient Journey Webinar

Updated Category News Views 273

Unlocking Insights from Real-World Data in Healthcare In an upcoming free webinar, you can explore the transformative role of real-world data (RWD) in healthcare, particularly in understanding the patient journey. As a participant, you'll gain insights into the advantages and challenges associated with various RWD sources, including electronic health records (EHRs),...

Continue Reading
Cove Capital's New Industrial Acquisition for 1031 Investors

Updated Category News Views 56

Cove Capital Purchases New Industrial Asset Cove Capital Investments, LLC, an esteemed Delaware Statutory Trust sponsor company, has announced its latest venture: the acquisition of an industrial asset. This strategic purchase aligns with the firm's commitment to expanding its portfolio aimed at 1031 Exchange and direct cash investors. Investment Details and Goals In this...

Continue Reading
Pixalate Ranks Programmatic Ad Sellers in India for 2024

Updated Category News Views 194

Ranking the Best Programmatic Ad Sellers in India for 2024 Pixalate, an industry leader in ad fraud protection and compliance analytics, has recently published its Q3 2024 Seller Trust Index, which evaluates programmatic ad sellers across various platforms in India. This index provides valuable insights into which sellers achieve top-tier quality in the rapidly evolving...

Continue Reading